

Symphogen A/S

Pederstrupvej 93, 2750 Ballerup

CVR no. 10 01 32 67

Annual report 2023/24

Approved at the Company's annual general meeting on 24 March 2025

Chairman of the meeting:

Signed by:
Jacob Monberg
.....
B9413EAC6A8B426...

Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements 1 October 2023 - 30 September 2024	10
Income statement	10
Balance sheet	11
Statement of changes in equity	13
Cash flow statement	14
Notes to the financial statements	15

Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Symphogen A/S for the financial year 1 October 2023 - 30 September 2024.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 30 September 2024 and of the results of the Company's operations and cash flows for the financial year 1 October 2023 - 30 September 2024.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Ballerup, 24 March 2025

Executive Board:

DocuSigned by:



F06CB18039D3478

Christophe Thurieau
Chief Executive Officer

Board of Directors:

DocuSigned by:



89897EEFGD41431

Claude Philippe Bertrand
Chairman

DocuSigned by:



E06CB18039D3478

Christophe Thurieau

Signé par :



602C0E09D4264D9

Benoit Alain Antoine
Chéron

DocuSigned by:



B03DEF7BD338B45C

Pascal Lemaire

Independent auditor's report

To the shareholder of Symphogen A/S

Opinion

We have audited the financial statements of Symphogen A/S for the financial year 1 October 2023 - 30 September 2024, which comprise income statement, balance sheet, statement of changes in equity, cash flow statement and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 30 September 2024 and of the results of the Company's operations as well as the cash flows for the financial year 1 October 2023 - 30 September 2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Independent auditor's report

- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.


Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 24 March 2025
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Allan Nørgaard
State Authorised Public Accountant
mne35501

Management's review

Company details

Name	Symphogen A/S
Address, Postal code, City	Pederstrupvej 93, 2750 Ballerup
CVR no.	10 01 32 67
Established	1 January 2000
Registered office	Ballerup
E-mail	info@symphogen.com
Telephone	+45 45 26 50 50
Board of Directors	Claude Philippe Bertrand, Chairman Christophe Thurieau Benoit Alain Antoine Chéron Pascal Lemaire
Executive Board	Christophe Thurieau, Chief Executive Officer
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

Management's review

Financial highlights

DKK'000	2023/24	2022/23	2021/22	2020/21	2019/20
Key figures					
Revenue	474,730	471,468	70,019	458,964	112,600
Operating profit/loss	43,349	38,707	-336,386	94,496	-188,755
Net financials	-5,784	-6,858	1,857	-4,644	-24,044
Profit for the year	37,336	49,113	165,734	86,877	-204,707
Total assets	422,808	368,203	303,252	285,011	315,470
Investments in property, plant and equipment	27,440	38,523	18,237	9,737	100,939
Equity	223,724	186,388	137,275	-28,459	-115,336
Cash flows from operating activities	87,772	2,920	3,586	2,442	-309,711
Net cash flows from investing activities	-27,440	-27,170	-18,237	-9,737	100,939
Cash flows from financing activities	-14,045	-15,776	-14,204	-11,244	219,679
Total cash flows	46,287	-40,026	-28,855	-18,539	10,907
Financial ratios					
Equity ratio	52.9%	50.6%	45.3%	-10.0%	-36.6%
Return on equity	18.2%	30.3%	304.6%	-120.8%	-70.1%
Operating margin	9.1%	8.2%	280.4%	20.6%	-167.6%

The financial ratios stated under "Financial highlights" have been calculated as follows:

Operating profit/loss	Profit/loss before net financials +/- Other operating income and other operating expenses
Equity ratio	$\frac{\text{Equity, year-end} \times 100}{\text{Total equity and liabilities, year-end}}$
Return on equity	$\frac{\text{Profit/loss after tax} \times 100}{\text{Average equity}}$
Operating margin	$\frac{\text{Operating profit/loss} \times 100}{\text{Revenue}}$

In 2020, Symphogen changed its financial year from January 1 - December 31 to October 1 September 30. The comparatives information for 2020 comprise a nine-month period.

Management's review

Business review

Symphogen A/S serve as a Centre of Excellence for discovery and development of Antibody Therapeutics as a service provider to Les Laboratoires Servier under a cost plus service agreement to pursue antibody discovery and development.

Symphogen A/S applies our highly efficient antibody platform and capabilities in the discovery and early development of new and differentiated antibody therapeutics through improved research technologies.

Symphogen A/S was founded in 2000 and became part of the Servier Group in June 2020 to support Servier's commitment to improving patients' health and the R&D strategy within oncology and immuno-oncology through antibody therapeutics.

Antibodies are the human body's natural defense system designed to resist and fight disease. Our mission is to find innovative scientific solutions to overcome the biological mechanisms leading to cancer or immuno-inflammatory diseases by lever. We strive for making discoveries that can majorly impact the lives of patients and their families.

Recognition and measurement uncertainties

Symphogen A/S is subject to income tax regulation in Denmark. Considering the complex nature, associated with transactions implying the transfer of intellectual property rights and the various estimates and judgments made about such transactions, Symphogen has recognized a provision for uncertain tax positions of DKK 25 million as of September 30, 2024. Due to the uncertainties, the provision for uncertain tax positions may deviate from the actual obligation. Refer to note 16 in the financial statements.

Financial review

Our revenue increased from DKK 471 million in 2022/2023 to DKK 475 million in 2023/2024.

The net result for the year ending 30th September 2024, amounted to a profit of DKK 37 million compared to a profit of DKK 49 million for the year ending 30th September 2023

On 30th September 2024, the total equity amounted to DKK 224 million and the total assets amounted to DKK 423 million.

Development in 2023/2024 compared to prior years expressed expectations

In the financial statement for 2022 /23, our outlook for 2023/24 expressed expected revenue for 2023/2024 within the range of DKK 500-525 million and net result within the range of DKK 30-35 million.

Investments

Investments amounted to DKK 27 million in 2023/2024 against DKK 38 million in 2022/2023. Mainly driven by investments in laboratory equipment and capacities.

Management's review

Change in share capital

In March 2023, the Company changed its share capital structure and closed and merged the share classes D, J, and L into one single share class. Following the change and on September 30, 2024, Symphogen's share capital amounts to DKK 11,292,369 divided into shares of DKK 1.

Knowledge resources

Symphogen A/S is a knowledge-based organization with a highly science-focused workforce, whereof approximately 82% of the employees are involved in rendering R&D service activities.

Impact on the external environment

Symphogen A/S is taking part in the overall Servier Group CSR initiatives and especially focusing on the environment, health of employees, diversity, and inclusion.

Research and development activities

Symphogen A/S is a fully owned subsidiary of Servier Group and renders R&D services to Servier mainly performing, discovery, and early and late-stage research activities, including lead identification, selection, and development of biologic investigational medical products. Moreover, Symphogen supports Servier R&D with management of clinical studies and regulatory affairs activities. Symphogen is at the present time involved in approximately 16 active therapeutic projects owned by Servier.

Statutory CSR report

Symphogen is taking part in the overall Servier CSR initiatives and especially focusing on the environment, health of employees, diversity, and inclusion.

For our statutory report on corporate social responsibility cf. section 99a reference to Servier Group sustainability report 2023/24.

<https://www.symphogen.com/wp-content/uploads/2025/03/Sustainability-Report-Financial-Year-2023-2024.pdf>

Report on the gender composition of Management

Symphogen believes in diversity among employees, including equal gender distribution, and works purposefully towards this whenever possible. The gender composition of Symphogen's Board of Directors and senior management level is listed below the Financial highlights.

The gender composition in Symphogen reflect the general composition in the pharma industry – per 30th September 2024, 67% (100 females) and 33% (49 males).

For many years it has been seen that there is more woman than men that graduate from the universities and seek job in the pharma industry Symphogen operates within.

Symphogen's recruitment process don't select candidates based on gender but based on their education and expertise within the pharma industry.

Management's review

Overview

	2023/24
--	---------

Supreme governing body

Total number of members	4
Underrepresented gender in %	0
Target figure in %	50
Year in which the target figure is expected to be met	2027

Other levels of management

Total number of members	16
Underrepresented gender in %	32
Target figure in %	50
Year in which the target figure is expected to be met	2027

Supreme governing body

Board members are selected by our parent company Les Laboratoires Servier, based on their position and experience in the Servier Group.

Other levels of management

The company's other levels of management consist of the company's Line Management, as well as Senior Management, who report directly to the registered executive board. Line Management members are based on education and expertise selected as department heads within their respective fields of expertise within Research, CMC and Business Support. Senior Management members are select by GM Manager based on education and expertise and at the same time to ensure an interdisciplinary cross-section of the Symphogen organization.

Outlook

Symphogen is working under a Les Laboratoires Servier service agreement and will continue its work to provide new antibody therapeutic candidates, Improved research technologies and to establish platforms for new therapeutic modalities.

Furthermore, under this agreement, Symphogen will continue to optimize the late research and early development capabilities, to conduct IND-enabling activities and participate in both early and later-stage projects.

In 2024/2025, Symphogen will continue to provide new antibodies with unique functionalities both within the oncology and immuno-inflammatory space, aiming to be best or first in class, thereby leveraging opportunities to develop innovative therapeutics. Symphogen will also continue conducting cross-national clinical programs in collaboration with global R&D, participating in partnered programs at different stages {e.g. CMC development) and further develop and strengthen its discovery and pre-clinical capabilities.

It is foreseen that the company will take on additional early research-stage projects during this period.

Revenue for 2024/25 is expected to be within the range of DKK 525-535 million and the net result for 2024/25 is expected to be within the range of DKK 25-35 million.

Financial statements 1 October 2023 - 30 September 2024

Income statement

Note	DKK'000	2023/24	2022/23
4	Revenue	474,730	471,468
8	Other external expenses	-254,110	-265,536
	Gross profit	220,620	205,932
9	Staff costs	-152,692	-139,397
	Amortisation/depreciation and impairment of intangible assets and property, plant and equipment	-24,579	-27,828
	Profit before net financials	43,349	38,707
5	Financial income	921	993
6	Financial expenses	-6,705	-7,851
	Profit before tax	37,565	31,849
7	Tax for the year	-229	17,264
	Profit for the year	37,336	49,113

Financial statements 1 October 2023 - 30 September 2024

Balance sheet

Note	DKK'000	2023/24	2022/23
	ASSETS		
	Non-current assets		
11	Property, plant and equipment		
	Laboratory equipment	51,303	38,937
	Fixtures and fittings, other plant and equipment	3,006	5,175
	Leasehold Improvements	6,780	4,275
	Right to use assets	73,593	83,436
		<u>134,682</u>	<u>131,823</u>
12	Financial assets		
	Prepayments	9,097	12,820
	Leasehold deposits	4,401	4,401
13,17	Deferred tax assets	19,081	19,081
		<u>32,579</u>	<u>36,302</u>
	Total non-current assets	<u>167,261</u>	<u>168,125</u>
	Current assets		
	Receivables		
	Receivables from group enterprises	139,703	152,707
	Other receivables	29,644	18,453
14	Prepayments	26,130	14,989
		<u>195,477</u>	<u>186,149</u>
	Cash	60,070	13,929
	Total current assets	<u>255,547</u>	<u>200,078</u>
	TOTAL ASSETS	<u>422,808</u>	<u>368,203</u>

Financial statements 1 October 2023 - 30 September 2024

Balance sheet

Note	DKK'000	2023/24	2022/23
	EQUITY AND LIABILITIES		
	Equity		
15	Share capital	11,292	11,292
	Share premium account	1,006,541	1,006,541
	Retained earnings	-894,109	-831,445
	Dividend proposed	100,000	0
	Total equity	223,724	186,388
	Liabilities		
16	Non-current liabilities		
	Lease liabilities	68,727	78,278
	Corporation tax payable	24,800	22,400
	Total non-current liabilities	93,527	100,678
	Current liabilities		
16	Lease liabilities	9,505	8,094
	Trade payables	51,139	26,879
16	Corporation tax payable	1,230	13,171
	Other payables	43,683	32,993
	Total current liabilities	105,557	81,137
	Total liabilities	199,084	181,815
	TOTAL EQUITY AND LIABILITIES	422,808	368,203

- 1 Accounting policies
- 2 Recognition and measurement uncertainties
- 3 Events after the balance sheet date
- 9 Staff costs
- 10 Appropriation of profit
- 13 Deferred tax assets
- 18 Contractual obligations and contingencies, etc.
- 19 Contingent assets
- 20 Related parties

Financial statements 1 October 2023 - 30 September 2024

Statement of changes in equity

Note	DKK'000	Share capital	Share premium account	Retained earnings	Dividend proposed	Total
	Equity at					
	1 October 2022	11,292	1,006,541	-880,558	0	137,275
10	Transfer, see					
	"Appropriation of profit"	0	0	49,113	0	49,113
	Equity at					
	1 October 2023	11,292	1,006,541	-831,445	0	186,388
10	Transfer, see					
	"Appropriation of profit"	0	0	-62,664	0	-62,664
	Dividend	0	0	0	100,000	100,000
	Equity at					
	30 September 2024	11,292	1,006,541	-894,109	100,000	223,724

Financial statements 1 October 2023 - 30 September 2024

Cash flow statement

Note	DKK'000	2023/24	2022/23
	Profit for the year	37,336	49,113
21	Adjustments	20,954	30,962
	Cash generated from operations (operating activities)	58,290	80,075
22	Changes in working capital	29,346	-74,929
	Cash generated from operations (operating activities)	87,636	5,146
	Interest received, etc.	284	14
	Interest paid, etc.	-1,136	-2,240
	Income taxes paid	988	0
	Cash flows from operating activities	87,772	2,920
	Additions of property, plant and equipment	-27,440	-27,170
	Cash flows to investing activities	-27,440	-27,170
	Payment of leasing liability	-14,045	-15,776
	Cash flows from financing activities	-14,045	-15,776
	Net cash flow	46,287	-40,026
	Cash and cash equivalents at 1 October	13,929	54,168
	Foreign exchange adjustments	-146	-213
	Cash and cash equivalents at 30 September	60,070	13,929

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies

The annual report of Symphogen A/S for 2023/24 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

The financial statements have been prepared on a going concern basis.

Reporting currency

The financial statements are presented in Danish kroner (DKK'000).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

Income statement

Revenue

The Company has chosen IFRS 15 as interpretation for revenue recognition.

Symphogen generates revenue under a service agreement entered with Servier, under which Symphogen renders research and development services concerning intellectual property and projects owned by Servier. Under the terms of the service agreement, Symphogen receive remuneration corresponding to the actual operating expenses incurred for the performance of the research and development services with a mark-up.

Revenue is measured at the fair value of the consideration received or receivable, considering contractually defined terms of payment and excluding taxes or duty.

Revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements, the following five steps are performed: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The five-step model to contracts is only applied when it is probable that the consideration Symphogen is entitled to in exchange for the goods or services it transfers to the customer will be collected. At contract inception, Symphogen assesses the goods or services promised within each contract and identifies, as a performance obligation, and assesses whether each promised good or service is distinct. Revenue is recognized in the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Revenue from rendering of research and development services is recognized over the service period, over time, given that customer simultaneously receives and consumes the benefits of the research and development services rendered.

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to rendering of research and development services, administration, premises, bad debts, etc.

Staff costs

Wages and salaries, bonuses, pensions, severance payments, social security expenses and other staff expenses are recognized in the year in which the associated services are rendered by employees of Symphogen.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

Depreciation

The item comprises depreciation of property, plant and equipment.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Laboratory equipment	6 years
Fixtures and fittings, other plant and equipment	3-6 years
Leasehold Improvements	Lifetime of lease contracts and up to 10 years
Right of use assets	The lifetime of lease contracts years

Depreciation is based on the residual value of the asset and is reduced by impairment losses, if any. The depreciation period and the residual value are determined at the acquisition date and are reassessed annually. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised.

In the case of changes in the depreciation period or the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

Financial income and expenses

Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses, allowances and surcharges under the advance-payment-of-tax scheme, as well as realized and unrealized gains and losses on transactions denominated in foreign currencies etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

Balance sheet

Property, plant and equipment

Property, plant and equipment include leasehold improvements, laboratory equipment and other equipment. Property, plant, and equipment are measured at cost less accumulated depreciation and impairment. The cost includes the cost of acquisition and expenses directly related to the acquisition until such time when the asset is available for use.

Right of use assets

Right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

Leases

The Company has chosen IFRS 16 as interpretation for classification and recognition of leases.

On initial recognition, leases for assets that transfer substantially all the risks and rewards incident to the ownership to the Company (finance leases) are measured in the balance sheet at the lower of fair value and the present value of the future lease payments. In calculating the net present value, the interest rate implicit in the lease or the incremental borrowing rate is used as the discount factor. Assets held under finance leases are subsequently accounted for in the same way as the Company's other assets.

The capitalised residual lease liability is recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement over the term of the lease.

Impairment of non-current assets

The carrying amount of non current assets, including property, plant and equipment and right of use lease assets is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists.

Receivables

The company has chosen IFRS 9 as interpretation for impairment write-down of financial receivables.

Receivables from collaboration partners, group companies, and other receivables are designated as receivables and are initially measured at fair value or transaction price and subsequently measured in the balance sheet at amortized cost, which generally corresponds to nominal value less expected credit loss provision.

Symphogen to record an allowance for expected credit losses for receivables and other receivables not held at fair value through profit and loss. Expected credit losses are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that Symphogen expects to receive.

For receivables with collaboration partners, group companies, and other receivables, Symphogen has applied the standard's simplified approach and has calculated expected credit losses based on lifetime expected credit losses.

Prepayments

Prepayments include expenditures related to future financial periods and are measured at nominal value.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

Cash

Cash comprise cash in bank.

Income taxes and Deferred taxes

The Symphogen is subject to the Danish rules on compulsory joint taxation with other Danish group companies. On payment of joint taxation contributions, the Danish corporation tax charge is allocated between the jointly taxed entities in proportion to their taxable income. Entities with tax losses receive joint taxation contributions from entities that have been able to use the tax losses to reduce their own taxable income.

Tax for the year comprises current income tax, joint taxation contribution and changes in deferred tax for the year due to changes in the tax rate. The tax expense relating to the profit/loss for the year is recognized in the statement of profit or loss, except to the extent that it relates to items recognized in equity or in other comprehensive income. Current tax payables and receivables are recognized in the balance sheet as a receivable in the event of prepayments and amounts due.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alter-native tax rules, deferred tax is measured based on the planned use of the asset or the settlement of the obligation. Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set of within the same legal tax entity and jurisdiction.

Current tax assets for the current and prior periods shall be measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Uncertain tax position

The Company carries out potentially complex transactions that require management to make judgments and estimates as to the tax impact of those transactions. The positions adopted by the Company in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, the Company assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information, that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice, and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of the Company's best estimate and recognized as a liability uncertain tax assets are not recognised. Tax exposures relating to corporate income taxes are presented separately within non-current income tax liabilities.

Liabilities

The Company has chosen IAS 39 as interpretation for liabilities.

Other liabilities are initially measured at fair value adjusted for transaction costs. Subsequently, other liabilities are measured at amortized cost which generally corresponds to nominal value. Payables related to research and development clinical trials comprise professional fees, pass through costs and investigator fees related to the conduct of clinical trials. Employee cost liabilities comprise provision for holiday allowance, provision for salaries and other employee related provisions.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

Lease liabilities

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Symphogen's incremental borrowing rate. Generally, Symphogen uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments.
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date.
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that Symphogen is reasonably certain to exercise, lease payments in an optional renewal period if Symphogen is reasonably certain to exercise an extension option and penalties for early termination of a lease unless Symphogen is reasonably certain not to terminate early.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in Symphogen's estimate of the amount expected to be payable under a residual value guarantee, or if Symphogen changes its assessment of whether it will exercise a purchase, extension, or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Symphogen presents right of use assets that do not meet the definition of investment property in property plant and equipment and lease liabilities in loans and borrowings in the statement of financial position.

Short-term leases and leases of low-value assets

Symphogen has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less and leases of low-value assets. Symphogen recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

Reassessment of the lease liability

Symphogen remeasures the carrying amount of its lease liabilities to reflect reassessments or revised in-substance fixed payments by discounting the revised lease payments. When the change in lease payments results from a change in floating interest rates, Symphogen uses a revised discount rate that reflects changes in the interest rate. Symphogen recognizes the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset.

Cash flow statement

The cash flow statement shows the Company's net cash flows broken down according to operating, investing and financing activities, the year's changes in cash and cash equivalents as well as the cash and cash equivalents at the beginning and the end of the year.

Cash flows from operating activities are calculated as the profit/loss for the year adjusted for non cash operating items, changes in working capital and paid corporate income tax.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

1 Accounting policies (continued)

Cash flows from investing activities comprise payments in connection with acquisitions and disposals of entities and activities and of intangible assets, property, plant and equipment and investments.

Cash flows from financing activities comprise changes in the size or composition of the Company's share capital and related expenses as well as raising of loans, repayment of interest bearing debt and payment of dividends to shareholders.

Cash and cash equivalents comprise cash, short term bank loans and short term securities which are readily convertible into cash and which are subject only to insignificant risks of changes in value.

2 Recognition and measurement uncertainties

Refer to note 16 and 17 for description of recognition and measurement uncertainties relating to uncertain tax positions and deferred tax assets.

3 Events after the balance sheet date

No events that could significantly affect the financial statements have occurred after the reporting period closing date.

DKK'000	2023/24	2022/23
4 Segment information		
Breakdown of revenue by business segment:		
Revenue from Services Agreement with Les Laboratoires Servier SAS	474,730	471,468
	<u>474,730</u>	<u>471,468</u>
Breakdown of revenue by geographical segment:		
France	474,730	471,468
	<u>474,730</u>	<u>471,468</u>

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

DKK'000	2023/24	2022/23
5 Financial income		
Other interest income	490	14
Exchange gain	431	979
	<u>921</u>	<u>993</u>
6 Financial expenses		
Interest expenses, group entities	1,136	2,225
Other interest expenses	5,337	2,415
Exchange losses	576	1,196
Interest expense, leasing liabilities	2,056	2,015
Other financial expenses	-2,400	0
	<u>6,705</u>	<u>7,851</u>
7 Tax for the year		
Estimated tax charge for the year	671	1,817
Deferred tax adjustments in the year	0	-19,081
Tax adjustments, prior years	-442	0
	<u>229</u>	<u>-17,264</u>
8 Fee to the auditors appointed in general meeting		
Statutory audit	629	598
Tax assistance	83	65
	<u>712</u>	<u>663</u>
9 Staff costs		
Wages/salaries	131,676	112,594
Pensions	11,101	18,184
Other social security costs	1,256	1,325
Other staff costs	8,659	7,294
	<u>152,692</u>	<u>139,397</u>
Average number of full-time employees	<u>154</u>	<u>144</u>
By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to Management is not disclosed.		
Remuneration of the Board of Directors is paid by the parent Company.		
10 Appropriation of profit		
Recommended appropriation of profit		
Proposed dividend recognised under equity	100,000	0
Retained earnings/accumulated loss	-62,664	49,113
	<u>37,336</u>	<u>49,113</u>

Based on the current and previous years' results, it is recommended that a dividend of 100 million DKK to be paid out for 2023/24.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

11 Property, plant and equipment

DKK'000	Laboratory equipment	Fixtures and fittings, other plant and equipment	Leasehold Improvements	Right to use assets	Total
Cost at 1 October 2023	146,133	27,483	27,814	142,835	344,265
Additions	23,980	342	3,118	0	27,440
Cost at 30 September 2024	170,113	27,825	30,932	142,835	371,705
Impairment losses and depreciation at 1 October 2023	107,196	22,308	23,539	59,399	212,442
Depreciation	11,614	2,511	613	9,843	24,581
Impairment losses and depreciation at 30 September 2024	118,810	24,819	24,152	69,242	237,023
Carrying amount at 30 September 2024	51,303	3,006	6,780	73,593	134,682

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

12 Financial assets

DKK'000	Prepayments	Leasehold deposits	Total
Cost at 1 October 2023	12,820	4,401	17,221
Disposals	-3,723	0	-3,723
Cost at 30 September 2024	9,097	4,401	13,498
Carrying amount at 30 September 2024	9,097	4,401	13,498

Prepayments include accrual of expenses relating to subsequent financial years, primarily prepayments for clinical trials.

13 Deferred tax assets

Refer to note 17.

14 Prepayments

Prepayments include accrual of expenses relating to subsequent financial years, including prepayments relating to clinical trials of DKK 10,674 thousand and other prepaid costs, DKK 4,114 thousand.

15 Share capital

At September 30, 2022, the share capital consisted of DKK 0 class D shares (common shares), DKK 7,434,726 class J shares (preferred shares) and DKK 3,857,643 class L shares (preferred shares). Class J shares and class L shares were convertible into common shares in certain situations and subject to certain terms and conditions.

In March 2023, the Company changed its share capital structure and closed and merged the share classes D, J, L into one single share class. Following the change and on September 30, 2023, Symphogen's share capital amounts to DKK 11,292,369 divided into shares of DKK 1.

There has been no changes in share capital in the financial year 2023/24.

16 Non-current liabilities

DKK'000	Total debt at 30/9 2024	Short-term portion	Long-term portion	Outstanding debt after 5 years
Lease liabilities	78,232	9,505	68,727	26,910
Corporation tax payable	26,030	1,230	24,800	0
	104,262	10,735	93,527	26,910

Uncertain tax positions

Of corporation tax payable DKK 24.8 million relates to provisions for uncertain tax positions at 30 September 2024. Symphogen is subject to income taxes regulation in Denmark. Considering the complexity, by nature, associated with transactions implying the transfer of intellectual property rights in 2021/22 and the various estimates and judgements made in relation to such transactions, Symphogen has recognized a provision for uncertain tax positions of DKK 24.8 million. Due to the uncertainties, the provision for uncertain tax positions may deviate from the actual obligation.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

DKK'000	2023/24	2022/23
17 Deferred tax		
Deferred tax at 1 October	-19,081	0
Adjustment of deferred tax	0	-19,081
Deferred tax at 30 September	-19,081	-19,081

Symphogen has capitalized deferred tax assets of DKK 19,081 thousand. The capitalization of deferred tax assets from loss carry forward is based on expected and budgeted net taxable income for Symphogen for the next three income years, derived from research and development service to be rendered under the R&D service contract with Servier.

In addition, the company has further deferred tax assets of DKK 511 million, mainly related to tax loss carry-forwards, which not have been capitalized due to the uncertainty as to future utilization.

18 Contractual obligations and contingencies, etc.

On June 3, 2020, Symphogen entered the jointly taxation with other Danish subsidiaries and Branches of Les Laboratoires Servier. Symphogen has unlimited joint and several liability for payment of Danish corporation taxes within the joint taxation.

19 Contingent assets

In accordance with IP sales agreement, the company may be entitled to future milestone payments.

For contingent assets relating to tax loss carry forward refer to note 17.

Financial statements 1 October 2023 - 30 September 2024

Notes to the financial statements

20 Related parties

Symphogen A/S' related parties comprise the following:

Parties exercising control

Related party	Domicile	Basis for control
Les Laboratoires Servier	France	Participating interest

Information about consolidated financial statements

Parent	Domicile	Requisitioning of the parent company's consolidated financial statements
Les Laboratories Servier	50 Rue Carnot 92150 Suresnes France	The financial statements are not made available to the public

Related party transactions

Symphogen A/S was engaged in the below related party transactions:

DKK'000	2023/24	2022/23
Revenue from research and development services rendered to Les Laboratoires Servier	474,730	471,468
Revenue from rent and other facility services to group companies	363	363
Intercompany receivable	139,703	152,707

Symphogen's related parties comprise the shareholder of Symphogen the Executive Management team and the Board of Directors. Symphogen A/S has not granted any loans, guarantees, or other commitments to or on behalf of any of the members in the Board of Directors or Executive Management. Other than the remuneration and other transactions relating to the Board of Directors and Executive Management described in note 5, no other significant transactions have taken place with the Board of Directors or the Executive Management during 2023/2024.

Revenue to related parties " Les Laboratoires Servier" is invoiced monthly based on actually operating expenses incurred for the performance of the Services to LLS, to which a mark-up is added.

DKK'000	2023/24	2022/23
21 Adjustments		
Over-/underfunding	-2,400	2,400
Other adjustments	23,354	28,562
	20,954	30,962
22 Changes in working capital		
Change in non-current receivables	3,723	0
Other changes in working capital	25,623	-74,929
	29,346	-74,929